KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Receivables: 2009-2024

Historic Change in Receivables for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $57.9 million.

  • Biomarin Pharmaceutical's Change in Receivables fell 165.54% to -$48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year decrease of 81.57%. This contributed to the annual value of $57.9 million for FY2024, which is 69.59% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Change in Receivables stood at $57.9 million for FY2024, which was down 69.59% from $190.4 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Receivables registered a high of $190.4 million during FY2023, and its lowest value of -$65.6 million during FY2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Change in Receivables value was $82.0 million (recorded in 2022), while the average stood at $110.1 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 211.08% in 2021, then soared by 225.10% in 2022.
  • Biomarin Pharmaceutical's Change in Receivables (Yearly) stood at $59.0 million in 2020, then plummeted by 211.08% to -$65.6 million in 2021, then skyrocketed by 225.10% to $82.0 million in 2022, then soared by 132.14% to $190.4 million in 2023, then slumped by 69.59% to $57.9 million in 2024.